BeiGene reports H1 2024 R&D expenses by product; total R&D up 10% YoY to $915M

BeOne Medicines Ltd.

2024-Q2 EPS reported -$0.27 revenue$1,680,818,000

Zanubrutinib R&D expense $62.9M in H1 2024, down 22% from $81.1M in H1 2023.
Tislelizumab R&D expense $34.5M in H1 2024, down 27% from $47.0M in H1 2023.
Bcl-2 (BGB-11417) R&D expense $38.6M in H1 2024, up 120% from $17.5M in H1 2023.
Total R&D expense $915.1M in H1 2024 vs $831.3M in H1 2023, +10.1% YoY.
R&D collaboration projects $82.5M in H1 2024, up from $23.3M in H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.